Zevra Therapeutics plans to engage with the FDA in the second half of 2026 to discuss accelerating the clinical development of celiprolol for Vascular Ehlers-Danlos Syndrome. This engagement follows the enrollment of 66 patients in the Phase 3 DiSCOVER trial, with three confirmed events, indicating progress in the trial but also a potential desire to expedite the process.
Zevra Therapeutics disclosed that it enrolled four additional patients in its Phase 3 DiSCOVER trial for celiprolol during Q2 2026, bringing the total to 66 patients with three confirmed events. The key takeaway is the company's intention to engage with the FDA in H2 2026 to explore pathways to accelerate clinical development. This is significant because an accelerated pathway could potentially bring the drug to market sooner, impacting ZVRA's revenue timeline and competitive position. For traders, this presents a long-term opportunity if the FDA engagement is successful, but short-term impact is moderate as it's an exploratory discussion, not a definitive approval or acceleration. The risk lies in the uncertainty of FDA discussions and the trial's eventual outcome.